• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.

作者信息

Nissen N I, Hansen H H, Pedersen H, Stroyer I, Dombernowsky P, Hessellund M

出版信息

Cancer Chemother Rep. 1975 Sep-Oct;59(5):1027-9.

PMID:1106845
Abstract
摘要

相似文献

1
Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.新型鬼臼毒素衍生物VP-16-213（NSC-141540）口服制剂用于晚期肿瘤疾病患者的临床试验。
Cancer Chemother Rep. 1975 Sep-Oct;59(5):1027-9.
2
Phase I trial of a new form of an oral administration of VP-16-213.新型口服VP-16-213的I期试验
Cancer Treat Rep. 1979 Mar;63(3):485-7.
3
Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.
Cancer Chemother Rep. 1975 Jul-Aug;59(4):737-42.
4
4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.4'-去甲基表鬼臼毒素9-(4,6-O-2-亚噻吩基-β-D-吡喃葡萄糖苷)(NSC-122819；VM-26)和4'-去甲基表鬼臼毒素9-(4,6-O-亚乙基-β-D-吡喃葡萄糖苷)(NSC-141540；VP-16-213)用于儿童癌症的初步观察
Cancer Chemother Rep. 1975 Jul-Aug;59(4):743-9.
5
Phase II study of etoposide for carcinoma of the prostate.依托泊苷用于前列腺癌的II期研究。
Cancer Treat Rep. 1986 Jun;70(6):771-2.
6
Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Gynecol Oncol. 1978 Feb;6(1):7-9. doi: 10.1016/0090-8258(78)90002-1.
7
Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.依托泊苷用于难治性多发性骨髓瘤的II期评估：一项东南癌症研究组试验
Cancer Treat Rep. 1986 Jun;70(6):801-2.
8
[Phase II study of etoposide (NK 171) in advanced hematological malignancies].依托泊苷（NK 171）用于晚期血液系统恶性肿瘤的II期研究
Gan To Kagaku Ryoho. 1984 Aug;11(8):1579-84.
9
Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Cancer Treat Rep. 1979 Aug;63(8):1231-9.
10
Podophyllotoxin derivative VP 16-213.鬼臼毒素衍生物VP 16 - 213
Cancer Chemother Pharmacol. 1979;3(2):71-80. doi: 10.1007/BF00254976.

引用本文的文献

1
A new iridoid glycoside and NO production inhibitory activity of compounds isolated from Russelia equisetiformis.从土木香状黄水枝中分离得到的一个新的环烯醚萜苷及具有抑制一氧化氮生成活性的化合物。
J Nat Med. 2012 Jan;66(1):227-32. doi: 10.1007/s11418-011-0569-z. Epub 2011 Aug 6.
2
Constituents of cultivated Agaricus blazei.栽培灵芝的成分。
J Nat Med. 2011 Apr;65(2):307-12. doi: 10.1007/s11418-010-0495-5. Epub 2011 Jan 18.
3
Rearranged ent-kauranes from the stems of Tricalysia dubia and their biological activities.
J Nat Med. 2008 Jul;62(3):314-20. doi: 10.1007/s11418-008-0248-x. Epub 2008 Apr 15.
4
Current development of podophyllotoxins.鬼臼毒素的当前发展情况。
Cancer Chemother Pharmacol. 1982;7(2-3):93-8. doi: 10.1007/BF00254528.
5
The clinical pharmacology of VM26 and VP16-213. A brief overview.VM26和VP16 - 213的临床药理学。简要概述。
Cancer Chemother Pharmacol. 1982;7(2-3):133-40. doi: 10.1007/BF00254535.
6
[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].依托泊苷（VP 16-213）——一种具有高抗肿瘤活性的鬼臼毒素衍生物（作者译）
Klin Wochenschr. 1981 Nov 2;59(21):1177-88. doi: 10.1007/BF01721212.
7
The clinical pharmacology of etoposide and teniposide.依托泊苷和替尼泊苷的临床药理学
Clin Pharmacokinet. 1987 Apr;12(4):223-52. doi: 10.2165/00003088-198712040-00001.
8
Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.依托泊苷和替尼泊苷。生物分析、代谢及临床药代动力学
Pharm Weekbl Sci. 1988 Jun 17;10(3):101-16. doi: 10.1007/BF01959294.
9
The effect of dose on the bioavailability of oral etoposide.剂量对口服依托泊苷生物利用度的影响。
Cancer Chemother Pharmacol. 1986;16(2):178-81. doi: 10.1007/BF00256172.
10
Podophyllotoxin derivative VP 16-213.鬼臼毒素衍生物VP 16 - 213
Cancer Chemother Pharmacol. 1979;3(2):71-80. doi: 10.1007/BF00254976.